Alkem Labs’ ₹533 Crore MP Expansion Plan Gets Land Allotment In Ujjain

Alkem Laboratories Ltd, on 18 March 2026, said it will invest up to ₹533 crore to set up a greenfield formulations manufacturing facility in Ujjain.

The company has received an allotment letter for around 30 acres of land from DMIC Vikram Udyogpuri Ltd in Phase 2 of the industrial area. The facility proposed will be established in stages, according to its long-term expansion plan.

Post announcement, Alkem Laboratories shares ended at ₹5,331.60, down marginally by ₹2.50 (0.047%) on the Bombay Stock Exchange (BSE).

Why Is Alkem Investing In A New Facility?

The forthcoming plant will focus on the production of formulations, a key area that supports both domestic sales and international shipments. This investment signals Alkem's intention to expand its manufacturing footprint and boost its capacity, anticipating future demand.

The staged implementation strategy allows the company to adjust its capital spending based on market conditions, while also maintaining operational flexibility.

How Did The Company Perform In The Recent Quarter?

Alkem Laboratories reported a 5% year-on-year rise in net profit to ₹626 crore in the December quarter. Revenue from operations increased by 1.5% to ₹3,374 crore, which means the company has been performing well in business.

Operating metrics also improved, with earnings before interest, tax, depreciation, and amortisation (EBITDA) rising 7.4% to ₹759 crore, while EBITDA margins expanded to 22.5%, compared to 21.3% in the year-ago period.

The company has remained diversified in its revenue mix, where the US accounts for 19.1% and other international markets 9.8% of the total sales. The company operates mainly across Latin America, Australia and Europe.

Also Read: Privatisation Push Slows As Investor Interest Fades

What Does This Mean For Investors?

To the investors, this action represents a capacity-based growth strategy that is supported by consistent operating performance. This investment reflects the belief of the management in the future demand visibility, particularly in the formulations segment, where margins are comparatively strong.

The gradual character of the project lowers the risk of execution and implies a disciplined approach towards capital allocation, as opposed to aggressive expansion. When done properly, the facility could be able to push incremental revenue, operating leverage, and margin support during the medium term.

However, investors should closely track adherence to timelines, capacity ramp-up, and return ratios, as greenfield projects typically take time to translate into earnings. The key trigger will be how efficiently this investment converts into sustainable growth and improved profitability.

Source:

CNBC TV18